"I've always been a big fan of putting into the market on a regular basis regardless of what is happening in the overall market," explains Chuck Carlson, long considered one of the advisory industry's leading experts on dividend reinvestment plans.

Here, the editor of The DRIP Investor offers a 10-stock "autopilot" portfolio that is diversified among 10 high quality dividend-paying stocks and requiring a monthly investment of under $500.

Carlson says, "If I've learned anything in the more than a quarter of a century of following the markets, it is this fact - buying stocks when you know you should (i.e. during sharp down moves) is really difficult. Our heads says we should; after all, substantial market downturns create the best values.

"But our emotions usually take control, thus making it very difficult to pull the trigger and put money into the market when stocks are falling.

"That's why I've always been a big fan of 401(k) plans. With these investment vehicles, investment programs are put on 'autopilot,' with dollars being put into the market on a regular basis (usually each paycheck) regardless of what is happening in the overall market.

"Fortunately, investors can duplicate the autopilot feature of 401(k) plans with their DRIP investments by taking advantage of automatic monthly investment features provided by most DRIPs.

TheStreet.com's Jim Cramer says its stunning buy of Rohm & Haas will get people thinking about an energy top.

Just when you thought it was safe to short anything, particularly anything with any commodity exposure, Dow Chemical (NYSE: DOW) (Cramer's Take) comes along and inexplicably pays a gigantic amount of money, $78 in cash, for Rohm & Haas (NYSE: ROH) (Cramer's Take)? My first thought was that it must be a joke. That is inconceivable. A hoax. Something perpetrated by frustrated longs to spook the shorts.

I mean, a chemical company? Two chemical companies? Ground Zero for slowing economic activity and raw costs? People unsure if Dow could even pay its nearly 5% yield? I mean, even last night on my show, I made fun of the idea that people are confusing Becton Dickinson (NYSE: BDX) (Cramer's Take), a medical supply company, with a chemical company because it uses resin.

Amazing.

MOST NOTEWORTHY: Amazon.com, PG & E and Centerplate were today's noteworthy upgrades:

• Citigroup upgraded shares of Amazon.com (NASDAQ: AMZN) to Buy from Hold and raised their target to $119 from $95 as they believe the recent weakness has created an attractive entry point and that Amazon has one of best Fundamental outlooks for 2008 among all U.S. internet stocks.
  
• The firm also upgraded PG & E (NYSE: PCG) to Buy from Hold on valuation, as they believe skepticism around the company's 8% EPS growth target is alredy priced into the stock.
  
• Centerplate Inc. (AMEX: CVP) was raised to Buy from Neutral at Piper on valuation following the recent weakness.

OTHER UPGRADES:

• CIBC upgraded Humana Inc. (NYSE: HUM) to Sector Outperformer from Sector Performer.
  
• JP Morgan raised its rating on Priceline.com (NASDAQ: PCLN) and Becton Dickinson & Co. (NYSE: BDX) to Overweight from Neutral.

MOST NOTEWORTHY: The medical supplies and devices sector, East West Bancorp, Tempur Pedic and AbitibiBowater were today's noteworthy initiations:

• Credit Suisse initiated the medical supplies and devices sector with a Market Weight rating and started shares of Edwards Lifesciences (NYSE: EW) and Becton, Dickinson and Co (NYSE: BDX) with Outperform ratings and Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX) with Neutral ratings.
  
• East West Bancorp (NASDAQ: EWBC) was initiated with a Buy rating and $36 target at B. Riley; the firm's target implies a 23.1% potential total return over the next twelve months including the stock's 1.35% dividend yield.
  
• Tempur Pedic (NYSE: TPX) was started with an Outperform rating at William Blair, as they find the current valuation attractive for long-term investor given the company's strong position in the specialty sleep products.
  
• Deutsche Bank resumed coverage of AbitibiBowater (NYSE: ABH) with a Hold rating and $29 target, citing the strength of the Canadian dollar and difficult newsprint fundamentals.

OTHER INITIATIONS:

• Banc of America initiated shares of JA Solar (NASDAQ: JASO) and Trina Solar (NYSE: TSL) with Buy ratings and targets of $73 and $76, and initiated Horizon Lines (NYSE: HRZ) and Solarfun Power (NASDAQ: SOLF) with Neutral ratings and targets of $34 and $14.

On last night's "MAD MONEY" on CNBC, Jim Cramer wanted to show defensive stocks in the medical industrial field. He has seen enough earnings from big companies and he is fed up with the Fed sitting around while the U.S. economy is slowing to a halt. He wants an "Ultimate Defensive Portfolio" of three stocks that are defensive but whose businesses are still growing. He even wanted to take out the companies that are only growing because of foreign business.

1) Bard (C.R.) (NYSE: BCR) is one stock he's been behind since 2005, and he is still behind it. Besides thinking it can still be bought, there is more to like on it, especially its catheter business, but its biopsy technology and the angioplasty operations as well.

2) Becton, Dickinson (NYSE: BDX) is a safe traditional medical device and diagnostics company. BDX has been up 31% since Cramer first recommended it, and he thinks it will go higher. More on BDX here.

3) Baxter International Inc. (NYSE: BAX) was Cramer's #3 spot as the best of breed, but he only wants to buy it now if it sells off. You can read what else he noted on it.

Back in February I came up with a list of 20 Defensive Stocks for a Crummy Market. After those 20 stocks, I even came up with a list of 15 Second Line Defensive Stocks. Many of my names were different than Cramer's names at the time. Some of my picks were medical and some were not, and most were chosen at a time that fear and panic were starting to come front and center. These picks that Cramer came up with are all different in that they may grow, and not only because of the weak dollar.

Jon Ogg is a partner at 24.7 Wall St.; he does not own securities in the companies he covers.

Chuck Carlson is the newsletter industry leader in DRIPs, or dividend reinvestment plans. Not surprisingly, then, his newsletter is called The DRIP Investor.

For those unfamiliar with these programs, DRIPs are dividend reinvestment plans, which are set up by companies to make it easier and more cost-effective for individual investors to buy and accumulate long-term positions by reinvesting dividends back into additional shares.

Usually, the commissions and other related costs of DRIPs are low, and in some cases, free. Says Carlson, "All things equal, a DRIP with no fees is better than one that charges fees."

He continues, "To be sure, I'm not suggesting investors should automatically discard a DRIP because it charges fees. Still, fees erode investment returns, so taking fees into account in your selection process makes sense."

To help investors find the most cost-effective way of building portfolios, the advisor has conducted a review of "fee-free" plans. Using a proprietary system that ranks 5,000 stocks based on over 100 metrics, he has developed a "starter portfolio" for those with limited investment funds. Such a starter portfolio, he notes, could be developed with as little as $1,000 to start.

He notes, "If I were constructing a reasonably diversified starter portfolio of six "fee-free" stocks, I would focus on the following issues: